# US 2015/0104431 A1 · Cardiac muscle repair or regeneration using bone marrow-derived stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104431 A1
- Document ID: US20150104431A1
- Status: Published application
- Kind: A1
- Application number: 14/493,864
- Filed: 2014-09-23
- Published: 2015-04-16
- Earliest claimed: 1997-07-14
- Assignees: Mesoblast International Sarl
- Applicants: Mesoblast International Sarl
- Inventors: Mark F. Pittenger; Stephen L. Gordon; Alastair Morgan Mackay
- Web page: https://patentgrep.com/patent/US20150104431A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/99: Serum-free medium
- C12N 2510/02: Cells for production
- C12N 2533/54: Collagen; Gelatin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

## Claims

### Claim 1

A cell preparation comprising adult bone marrow-derived stem cells in a dose effective to augment ventricular function in the heart of a subject in need thereof.

### Claim 2 (depends on 1)

The cell preparation of claim 1, wherein the stem cells are capable of differentiating into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

### Claim 3 (depends on 1)

The cell preparation of claim 1, wherein the dose comprises about 0.02 to about 150 milliliters of a pharmaceutically acceptable liquid medium and wherein the stem cells are at a concentration of about 10 to about 40 million cells per milliliter.

### Claim 4 (depends on 1)

The cell preparation of claim 1, wherein the stem cells have an induced expression of at least one cardiac specific marker.

### Claim 5 (depends on 4)

The cell preparation of claim 4, wherein the at least one cardiac specific marker is myosin heavy chain, sarcoplasmic reticulum calcium ATPase, or connexin 43.

### Claim 6 (depends on 4)

The cell preparation of claim 4, wherein the induced expression of at least one cardiac specific marker results from (i) co-culturing the stem cells with cardiac cells, (ii) use of chemical fusigens to create heterokaryons of the stem cells with cardiomyocytes, (iii) incubating the stem cells with extracts of mammalian hearts, (iv) treatment of the stem cells with growth factors, differentiating agents, or both, (v) mechanical or electrical stimulation of the stem cells, or (vi) mechanical or electrical coupling of the stem cells with cardiomyocytes.

### Claim 7 (depends on 1)

The cell preparation of claim 1, wherein the subject is a myocardial infarction patient, an ischemic heart transplant patient, a congestive heart failure patient, or a coronary artery bypass graft patient.

### Claim 8 (depends on 1)

The cell preparation of claim 1, wherein the cell preparation is capable of improving ventricular ejection fraction in the subject.

### Claim 9

A method of improving left ventricular ejection fraction in a patient comprising the step of:
administering to the patient adult bone marrow-derived stem cells in an amount effective to improve ventricular ejection fraction.

### Claim 10 (depends on 9)

The method of claim 9, wherein the stem cells are autologous to the patient.

### Claim 11 (depends on 9)

The method of claim 9, wherein the stem cells are administered intravenously or intraarterially.

### Claim 12 (depends on 9)

The method of claim 9, wherein the stem cell are administered directly to the heart.

### Claim 13 (depends on 9)

The method of claim 9, wherein the stem cells are mesenchymal stem cells.

### Claim 14

A method of treating a patient having myocardial infarction or congestive heart failure and having reduced cardiac function comprising the step of:
administering to the patient adult bone marrow-derived stem cells in an amount effective to improve cardiac function.

### Claim at position 15



### Claim 16 (depends on 14)

The method of claim 14, wherein the cells are autologous.

### Claim 17 (depends on 14)

The method of claim 14, wherein the stem cells are administered intravenously or intraarterially.

### Claim 18 (depends on 14)

The method of claim 14, wherein the stem cells are administered directly to the heart.

### Claim 19 (depends on 14)

The method of claim 14, further comprising the step of assessing cardiac function at a time after administering the stem cells, wherein the assessing comprises measuring at least one of left ventricular ejection fraction, ventricular end diastolic pressure, or ventricular wall motion.

### Claim 20 (depends on 14)

The method of claim 14, wherein the stem cells are mesenchymal stem cells.

### Claim 21

A method of augmenting ventricular function in a patient comprising the step of:
administering to the heart of the patient a cell suspension, wherein the cell suspension comprises adult bone marrow-derived stem cells and a pharmaceutically acceptable liquid medium.

### Claim 22 (depends on 19)

The method of claim 19, wherein the patient has a left ventricular ejection fraction of less than about 40%.

### Claim 23 (depends on 19)

The method of claim 19, wherein the stem cells are mesenchymal stem cells.
